Evidence map›Paper›PMID 25787914›Full record

ArticleLeukemia2015

Next-generation sequencing reveals clinically actionable molecular markers in myeloid sarcoma.

Z Li, F Stölzel, K Onel, M Sukhanova, M K Mirza, K L Yap, O Borinets, R A Larson, W Stock, M M Sasaki and 2 more

Abstract readLetter
In one paragraph

Article in Leukemia, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Isochromosome 17q; A Novel Finding in Myeloid Sarcoma.Journal of clinical and experimental hematopathology : JCEH · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Z LiDepartment of Human Genetics, The University of Chicago Medical Center, Chicago, IL, USA.
F StölzelMedizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus Dresden, Technical University Dresden, Dresden, Germany.
K OnelDepartment of Pediatrics, The University of Chicago Medical Center, Chicago, IL, USA.
M SukhanovaDepartment of Medicine, The University of Chicago Medical Center, Chicago, IL, USA.
M K MirzaDepartment of Pathology, The University of Chicago Medical Center, Chicago, IL, USA.
K L YapDepartment of Medicine, The University of Chicago Medical Center, Chicago, IL, USA.
O BorinetsDepartment of Medicine, The University of Chicago Medical Center, Chicago, IL, USA.
R A LarsonDepartment of Medicine, The University of Chicago Medical Center, Chicago, IL, USA.
W StockDepartment of Medicine, The University of Chicago Medical Center, Chicago, IL, USA.
M M SasakiDepartment of Pediatrics, The University of Chicago Medical Center, Chicago, IL, USA.
L JosephDepartment of Pathology, The University of Chicago Medical Center, Chicago, IL, USA.
G RacaDepartment of Medicine, The University of Chicago Medical Center, Chicago, IL, USA.

Funding

VIRAL ONCOLOGY CORE FACILITYP30CA014599 · NCI · UNIVERSITY OF CHICAGO · PI MARK W. LINGEN · 1985 to 2026
$122.1M
NCI NIH HHS P30 CA014599NCI NIH HHS P30 CA14599
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Gene Expression ProfilingAdultAgedBiomarkers, TumorFemaleFollow-Up StudiesHigh-Throughput Nucleotide SequencingHumansMaleMiddle AgedMutationNeoplasm StagingPrognosisSarcoma, MyeloidSequence Analysis, DNABiomarkers, Tumor

Identifiers

PMID25787914
PMCPMC4575593

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.